OR WAIT null SECS
Jennifer Grebow is editor-in-chief of Nutritional Outlook.
By binding to H. pylori, the Pylopass probiotic strain ensures that the entire “co-aggregate” (Pylopass bound to H. pylori) is excreted from the body intact instead of allowing the H. pylori to remain in the gut and change the gut’s microflora, the company says.
Chinese dietary supplement brand By-Health has launched a new product designed to help control the pathogenic stomach bacteria Helicobacter pylori. The product is formulated with Pylopass, which is a proprietary probiotic strain from German probiotic-ingredient supplier Organobalance GmbH.
According to Organobalance, “Pylopass is a proprietary strain of Lactobacillus reuteri which specifically co-aggregates with Helicobacter pylori in the stomach to reduce the bacterial load.” In other words, “the surface structures” on the Pylopass bacteria cause the bacteria to adhere to the surface structures of H. pylori. By binding to H. pylori, Pylopass ensures that the entire “co-aggregate” (Pylopass bound to H. pylori) is excreted from the body intact instead of allowing the H. pylori to remain in the gut and change the gut’s microflora, the company says.
According to Organobalance, the prevalence of H. pylori infection is especially high in China compared to Western countries. The company adds that resistance to most of the commonly used antibiotics to treat H. pylori has made conventional treatment even more difficult.
“New studies show that Pylopass can not only reduce the colonization of H. pylori in the stomach, but also improve the symptoms associated with gastritis and increase the efficacy of pharmaceutical treatment,” added Gilles Jequier, Organobalance’s commercial director, in a press release.